Biomarker Discovery & Development

Vaccine biomarkers are measurable biological indicators used to assess the physiological, toxicological, pharmacological or clinical significance of a vaccine. Vaccine biomarkers are crucial for many aspects of vaccine development and licensing, including combining the findings of preclinical studies with clinical studies, predicting potential adverse events, and predicting vaccine efficacy. Creative Biolabs is an expert in vaccine industry and we offer biomarker discovery and development services to evaluate vaccine efficacy, immunogenicity, safety, adjuvant benefits and manufacturing consistency.

Biomarker Discovery & Development - Creative Biolabs

Our Services:

  • We are developing biomarkers used as vaccine-dependent signatures to predict subject response and safety.

Gene expression features are being used to predict the prognosis of cancer, indicating that biomarker technology can facilitate clinical decision-making and open the door to patient-specific personalized medicine. However, in order to successfully apply the genomic signature to vaccine development, the complexity of innate and adaptive immune responses needs to be dissected and these responses to vaccines and natural infections will need to be carefully mapped to incorporate well-defined expression signatures. Furthermore, early signaling of the innate immune system is likely to yield valuable information about the final performance of the vaccine, especially those containing adjuvants that specifically stimulate the innate immune system. In addition, the genomic signatures have the potential to correlate with important clinical phenotypes such as immune protection and may enable the discovery of true correlation of protective immunity enabling the generation of broadly protective vaccines.

  • We focus on biomarker discovery and developments in vaccines against cancer and chronic disease.

Due to the increased role of vaccines in cancer, this may also be a focus of biomarker development in chronic disease. Although it is possible to induce specific T cells against tumor antigens, active immunotherapy against various cancers has a low clinical response rate, due in part to the advanced stages of the disease and the immune compromise status of the patients being treated. Furthermore, there is a general lack of understanding of the important antigens targeted with the vaccine strategy. Therefore, in order to increase the chances of success, it is important to understand the individual's tumor microenvironment and overall acceptance of the treatment to have a high-quality patient population and to set the stage for the identification of biologically relevant substances that predict the anti-tumor response.

  • We provide services to explore host genetic make-up that may modulate subject-specific adverse events or affect the quality of immune responses.

The use of bench-side studies using sera obtained from selected subjects undergoing adverse events during vaccine clinical trials may be a way to identify predictive biomarkers in the era of personalized medicine.

Biomarkers are essential components for many stages of the vaccine development pipeline, from disease biomarkers, to post marketing monitoring, which can be used to assay for the presence of off-target immune responses that could lead to autoimmune mediated issues. Creative Biolabs is an expert company for vaccine targeting discovery services. Contact us and get the best biomarker discovery and development services!


Our services are for research use only. We do not provide services directly to individuals.


Online Inquiry

Name:
*Phone:
*E-mail Address:
*Products or Services Interested:
Project Description:
*Verification Code:
Verification code
Click image to refresh the verification code.

CONTACT US

USA
45-1 Ramsey Road, Shirley, NY 11967, USA
Tel: 1-631-466-5530
Fax: 1-631-207-8356
Email: Europe
Heidenkampsweg 58, 20097 Hamburg, Germany
Tel: 44-207-097-1828 Email:


Follow us on

facebook   twitter   linked   blog

Shopping Basket